Investment Rating - The report gives the company an "Accumulate" rating with a target price of 14.24 RMB based on a 30x PE for 2026 [3]. Core Views - The company is a dual leader in the silicone and glyphosate industries, with performance expected to recover against a backdrop of reduced competition [1]. - The company has pioneered a circular economy model utilizing chlorine, phosphorus, and silicon, achieving over 90% utilization rates for these elements [1][21]. - The company has a 7% market share in the domestic silicone market, ranking fifth, and a 10% share in glyphosate, ranking third [1]. Summary by Sections 1. Business Overview - The company operates in three main sectors: crop protection, silicone materials, and new energy materials, with a focus on integrating phosphorus and silicon materials [14]. - The crop protection segment has developed a comprehensive system covering intermediates, active ingredients, and formulations, contributing to food security [14]. - The silicone materials segment has a complete industrial chain from upstream silicon mining to downstream product manufacturing, with products sold in over 130 countries [14]. 2. Silicone Materials - The supply-demand dynamics are improving, leading to a price recovery for silicone products, with DMC prices rising from 11,000 RMB/ton to 14,000 RMB/ton [1]. - The company has a silicone monomer capacity of 500,000 tons, with about 80% used for self-produced downstream products [1]. - The company’s downstream silicone capacity exceeds 200,000 tons, with a conversion rate above 45% [1]. 3. Agricultural Chemicals - Glyphosate prices are expected to improve due to the promotion of genetically modified crops, with domestic capacity at 813,000 tons, accounting for nearly 70% of global capacity [2]. - The company has an existing glyphosate capacity of 80,000 tons, with a formulation conversion rate above 70% [2]. - The product portfolio includes over 100 varieties of herbicides, insecticides, fungicides, and growth regulators, supporting an integrated development model [2]. 4. Profit Forecast and Valuation - Revenue projections for 2025-2027 are 147 billion, 171 billion, and 186 billion RMB, with corresponding net profits of 1.1 billion, 6.4 billion, and 9.1 billion RMB [3]. - The company is expected to see a significant profit recovery, with net profit growth rates of 113%, 484%, and 42% for the respective years [3]. - The report highlights the cyclical nature of the company's earnings, with a current focus on recovery from recent performance lows [3][24].

Investment Rating - The report assigns a "Buy" rating to the company, with a target price of 14.24 RMB based on a 30x PE for 2026 [3]. Core Views - The company is a dual leader in the silicone and glyphosate industries, with performance expected to recover against a backdrop of reduced competition [1]. - The company has pioneered a circular economy model utilizing chlorine, phosphorus, and silicon, achieving over 90% utilization rates for these elements [1][21]. - The company’s revenue and profit have been under pressure due to price declines in recent years, but improvements in supply and demand dynamics are anticipated to drive performance recovery [1][2]. Summary by Sections 1. Business Overview - The company operates in three main sectors: crop protection, silicone materials, and new energy materials, with a focus on integrating phosphorus and silicon materials [14]. - The crop protection segment has developed a comprehensive system covering intermediates, active ingredients, and formulations, contributing to food security [14]. - The silicone materials segment has a complete industrial chain from upstream silicon mining to downstream product manufacturing, with applications in over 130 countries [14]. 2. Silicone Materials - The company’s silicone segment is expected to benefit from improving supply-demand dynamics, with prices showing signs of recovery [1][54]. - The domestic market for silicone has a strong demand base, with a compound annual growth rate of over 10% in recent years [54]. - The company has a silicone monomer capacity of 500,000 tons, with approximately 80% used for self-produced downstream products [1]. 3. Glyphosate Sector - Glyphosate prices are expected to improve due to the promotion of genetically modified crops, with domestic production capacity constrained by policy [2]. - The company has a glyphosate active ingredient capacity of 80,000 tons, with a formulation conversion rate exceeding 70% [2]. - The company has developed a diverse product portfolio in the agricultural sector, including over 100 varieties of herbicides, insecticides, and fungicides [2]. 4. Financial Forecast and Valuation - The company is projected to achieve revenues of 147 billion RMB in 2025, with a net profit of 1.1 billion RMB, reflecting a significant recovery from previous lows [3]. - The earnings per share (EPS) are expected to grow from 0.081 RMB in 2025 to 0.673 RMB by 2027 [3]. - The report anticipates a recovery in profitability, with net profit expected to increase by 484% in 2026 [3]. 5. Market Position and Competitive Landscape - The company holds a 7% market share in the domestic silicone market, ranking fifth, and a 10% share in glyphosate, ranking third [1]. - The company’s revenue structure has shifted, with the agricultural segment's contribution increasing from 41% in 2020 to 49% in the first half of 2025 [24]. - The company’s profitability has shown volatility, particularly in the silicone materials segment, which has experienced significant fluctuations in gross margins [24].

北交所信息更新 农药"反内卷"与海外补库助 "走出泥泞"，亏损收窄迎破局 颖泰生物（920819.BJ） ——北交所信息更新 2026 年 02 月 12 日 投资评级：增持（维持） | 日期 | 2026/2/12 | | --- | --- | | 当前股价(元) | 3.91 | | 一年最高最低(元) | 5.09/3.31 | | 总市值(亿元) | 47.93 | | 流通市值(亿元) | 47.37 | | 总股本(亿股) | 12.26 | | 流通股本(亿股) | 12.12 | | 近 3 个月换手率(%) | 49.23 | 北交所研究团队 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 初步核算公司 2025 年归母净利润为-2.50 亿元，同比减亏 57.45% 公司发布 2025 年业绩快报，经过初步核算，公司 2025 年营收为 55.31 亿元，同 比下降 2.27%，归母净利润为-2.50 亿元，同比减亏 57.45%。2025 年农药行业呈 局部回暖、分化复苏态势，公司聚焦产品与基地布局，严格管控成本费用，持续 推进组织优化与 ...

北交所信息更新 农药"反内卷"与海外补库助 "走出泥泞"，亏损收窄迎破局 颖泰生物（920819.BJ） ——北交所信息更新 2026 年 02 月 12 日 投资评级：增持（维持） | 日期 | 2026/2/12 | | --- | --- | | 当前股价(元) | 3.91 | | 一年最高最低(元) | 5.09/3.31 | | 总市值(亿元) | 47.93 | | 流通市值(亿元) | 47.37 | | 总股本(亿股) | 12.26 | | 流通股本(亿股) | 12.12 | | 近 3 个月换手率(%) | 49.23 | 北交所研究团队 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 初步核算公司 2025 年归母净利润为-2.50 亿元，同比减亏 57.45% 公司发布 2025 年业绩快报，经过初步核算，公司 2025 年营收为 55.31 亿元，同 比下降 2.27%，归母净利润为-2.50 亿元，同比减亏 57.45%。2025 年农药行业呈 局部回暖、分化复苏态势，公司聚焦产品与基地布局，严格管控成本费用，持续 推进组织优化与 ...

Group 1: Shareholder Changes - The controlling shareholder, Jiuyuan Group, plans to transfer part of its shares through a public solicitation of transferees, which may lead to a change in control, pending approval from state-owned asset supervision authorities [2][6] Group 2: Project Development - The cyanide project at the Jingzhou base is still in the preliminary preparation stage, with specific implementation awaiting board approval, and the outcome of this project may impact the company's capacity layout [3] Group 3: Business Progress - The company, as the largest producer of glyphosate raw materials in China, will continue to promote the registration and market expansion of glyphosate in multiple overseas countries to seize growth opportunities. Additionally, the 20,000 tons/year enzymatic glyphosate project at the Hunan Jinshi base has been put into production and is operating normally [4] Group 4: Industry Policy and Environment - Following adjustments to the export tax rebate policy, market orders and prices for glyphosate may experience fluctuations. The company notes that product prices are influenced by multiple factors, including supply and demand and competition. Furthermore, the company supports the industry's anti-"involution" initiative and is committed to promoting sustainable development [5]

Core Insights - The 2026 Central Document emphasizes the integration of artificial intelligence with agriculture, promoting the development of agricultural bio-manufacturing as a new productive force [1][3][11] Group 1: Agricultural Bio-Manufacturing - Agricultural bio-manufacturing is expected to break the limitations of traditional agriculture, allowing for production that does not rely on climate or land resources [4][12] - Technologies such as molecular breeding, precision breeding, and gene editing can transform seeds, enabling the production of high-quality agricultural products in various regions [12][14] - The development of bio-manufacturing is crucial for ensuring food security in China, particularly in addressing the low self-sufficiency rate of soybeans, which is below 20% [4][12] Group 2: Technological Advancements - The integration of AI in agriculture is shifting practices from experience-based farming to data-driven management, enhancing efficiency through algorithms [3][11] - The transition to industrialized cell factory models in agriculture is significant for sustainable development, as demonstrated by the efficiency of bio-manufacturing processes [14] Group 3: Industry Initiatives - The first national agricultural bio-manufacturing innovation consortium was established in July 2025, led by major companies and research institutions [15] - Notable companies involved in agricultural bio-manufacturing include Dabeinong, Angel Yeast, and Meihua Biological, among others, which have products recognized in the first batch of bio-manufacturing landmark products [15][17]

Group 1 - The company has not yet commenced the construction of its annual production projects for 20,000 tons of precision glyphosate and 20,000 tons of L-glutamic acid [1]

Group 1: Company Performance - The company's 2025 annual performance improved due to increased demand for certain products, a rise in overall gross profit margin, and cost reduction efforts, resulting in a year-on-year performance increase [2] - The agricultural chemical industry remains competitive, with major pesticide product prices stabilizing at low levels, but there are signs of demand recovery and price increases for some products [2] Group 2: Market Outlook - The company is optimistic about the market potential for precision glyphosate, expecting continued growth in market demand due to product registrations, marketing efforts, and production technology improvements [2][3] - Following the cancellation of the export tax rebate policy, there have been changes in market orders and pricing, but overall product prices are still influenced by competition, supply and demand, and customer purchasing methods [3] Group 3: Project Developments - The cyanide project at the Jingzhou base is still in the preliminary stages, pending approval from the board of directors [3] - The company's bio-manufacturing platform in Hunan has successfully launched a 20,000 tons/year enzymatic precision glyphosate project, with normal production conditions [3] Group 4: Corporate Governance - The company is in the process of a potential change in controlling shareholder and actual controller, with a public solicitation for transferees announced, pending approval from relevant authorities [3] - There are currently no plans for an equity incentive program as this matter is still under discussion [4]

Group 1: Lier Chemical - Lier Chemical is a global leader in chlorinated pyridine herbicides and a leading company in glyphosate and refined glyphosate, with products sold in over 30 countries and regions [1] - The core growth logic is driven by the accelerated ban on glyphosate, with the market size for glyphosate expected to grow from 3 billion yuan in 2020 to 8 billion yuan in 2025, representing a compound annual growth rate (CAGR) of 22% [1] - Lier Chemical is the second company globally and the first in China to master the industrialization of cyanopyridine chlorination technology, with a total production capacity exceeding 50,000 tons per year, achieving full production and sales [1] - The company has a market share of over 70% globally, with more than 80% of its sales coming from long-term supply agreements, and both product categories are currently in a price increase cycle [1] - The company has seen its performance improve by over 100% for three consecutive quarters [1] Group 2: Shandong Heda - Shandong Heda is the absolute leader in cellulose ether in China and a core supplier of plant capsules globally, with raw materials sourced from cotton, wood, and bamboo [2] - The focus is on medical-grade and food-grade cellulose ether, with profit margins reaching 25% to over 35%, particularly for medical-grade cellulose ether, which sees annual price increases and growing margins [2] - The company has established long-term supply agreements with major domestic pharmaceutical companies such as Heng Rui and Shi Yao, as well as international firms like Pfizer, Novartis, and Bayer, supplying 15 out of the top 20 global pharmaceutical companies [2] - The global capsule market is over 30 billion yuan, with the share of plant capsules expected to increase from 15% in 2020 to 30% in 2025, reflecting a CAGR of over 20% as a clear trend to replace gelatin capsules [2] - Shandong Heda has a domestic production capacity of 20 billion capsules per year, with a $500 million investment in the U.S. to build a project with the same capacity, expected to be operational by Q3 2026 [2]

Group 1 - The pesticide industry is experiencing favorable policies that are accelerating the elimination of outdated production capacity, focusing on compliance and profitability recovery among leading companies [3][11] - A new policy effective from January 1, 2026, mandates "one certificate, one product," which will significantly reduce the number of market brands and enhance industry concentration, benefiting compliant enterprises with abundant registration resources [12][11] - The recent adjustment in export tax policies aims to address overcapacity and high-toxicity products, pushing the industry towards high-quality development centered on technology and branding [11][3] Group 2 - The North Exchange's chemical new materials sector saw an increase of 5.11% in the week of January 19-23, 2026, outperforming other sectors [24][25] - Key stocks in the chemical new materials sector, such as Meibang Technology and Tianli Composite, experienced significant weekly gains of 32.89% and 16.47%, respectively [32][34] - The overall market performance indicates a recovery trend, with the North Exchange 50 index closing at 1588.66 points, reflecting a weekly increase of 2.60% [24][27] Group 3 - Ying Tai Biological's net profit for 2025 is projected to be between -2.6 billion and -2.0 billion yuan, a significant improvement from -5.87 billion yuan in 2024, indicating a recovery in profitability [5][21] - Jilin Carbon Valley is expected to report a net profit of 1.80 to 2.20 billion yuan in 2025, representing a year-on-year growth of 92.81% to 135.66% [5][67] - The overall recovery in the pesticide sector is reflected in the net profit growth rates, which turned positive in the fourth quarter of 2024 and continued to improve in 2025 [20][23]